BIOLARGO INC (BLGO) Financials

BLGO

Trailing 12 months to June 30, 2026

Revenue $4.1M -70.9% YoY

Net Income -$18.8M -184.9% YoY

Operating Cash Flow -$10.3M -37.9% YoY

Gross Profit $1.6M -74.4% YoY

Market Cap $27.8M as of Oct 9, 2026

Price / Sales 6.8x on $4.1M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BLGO SEC filings page.

BIOLARGO INC (BLGO) reported $4.1M in revenue over the twelve months to Jun 30, 2026, down 70.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BLGO FY2025 2026-10-01

Revenue contraction exposed a fixed operating cost base, while heavier cash outflows were largely matched by external financing.

Gross margin held at 43.9% in FY2025 versus 44.2% in FY2024 even as revenue contracted, so the sharp operating deterioration was not primarily a cost-of-revenue problem. SG&A and R&D together reached $14.4M against $7.8M of revenue, leaving the business unable to absorb its operating base.

Cash conversion weakened materially: operating cash flow went from an outflow of $3.2M in FY2024 to $8.3M in FY2025. Financing cash flow of $8.2M in FY2025 nearly matched that outflow, indicating that reported cash needs were being met chiefly through financing rather than operations.

Leverage increased as the capital cushion narrowed: debt-to-equity rose from 0.1x in FY2024 to 0.5x in FY2025. Total equity fell from $8.9M to $4.0M, making the same operating losses more consequential for the balance sheet.

Financial Health Signals

Financial health score not available

BIOLARGO INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/8

BIOLARGO INC passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

BIOLARGO INC reported a net loss of $15.2M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

BIOLARGO INC reported an operating loss of $14.9M against $540K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.2M

YoY-55.1%

QoQ+11.9%

5Y CAGR+21.9%

10Y CAGR+41.4%

BIOLARGO INC generated $1.2M in revenue in Q2 2026. This represents a decrease of 55.1% from the same quarter a year earlier. Against the prior quarter it is up 11.9%.

EBITDA

-$3.7M

YoY-109.3%

QoQ-16.6%

BIOLARGO INC's EBITDA was -$3.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 109.3% from the same quarter a year earlier. Against the prior quarter it is down 16.6%.

Net Income

-$4.0M

YoY-112.5%

QoQ-17.5%

BIOLARGO INC reported -$4.0M in net income in Q2 2026. This represents a decrease of 112.5% from the same quarter a year earlier. Against the prior quarter it is down 17.5%.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$2.2M

YoY-37.0%

QoQ-46.9%

5Y CAGR+10.0%

10Y CAGR+9.4%

BIOLARGO INC held $2.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

329M

YoY+6.4%

QoQ+2.4%

5Y CAGR+7.6%

10Y CAGR+14.2%

BIOLARGO INC had 329M shares outstanding in Q2 2026. This represents an increase of 6.4% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

54.1%

YoY+2.9pp

QoQ+13.0pp

5Y change+10.8pp

10Y change-5.5pp

BIOLARGO INC's gross margin was 54.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.0 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.1M

YoY+103.4%

QoQ+20.0%

5Y CAGR+25.0%

10Y CAGR+12.7%

BIOLARGO INC invested $1.1M in research and development in Q2 2026. This represents an increase of 103.4% from the same quarter a year earlier. Against the prior quarter it is up 20.0%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

BLGO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BLGO quarterly income statement

Metric	TTM	FY25S-1	FY24S-1	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$4.1M	$7.8M-56.3%	$17.8M+45.4%	$12.2M+107.9%	$5.9M+132.5%	$2.5M+4.1%	$2.4M+30.7%	$1.9M+36.4%	$1.4M+164.3%	$516K+83.6%	$281K+120.3%	$128K+14.4%	$112K-33.6%	$168K+156.2%	$66K-58.0%	$156K
Cost of Revenue	$2.5M	$4.4M-56.1%	$9.9M+63.4%	$6.1M+100.7%	$3.0M+112.0%	$1.4M+18.6%	$1.2M+27.4%	$945K+27.2%	$743K+130.0%	$323K+205.1%	$106K+70.6%	$62K+10.8%	$56K+88.8%	$30K-25.5%	$40K-11.1%	$45K
Gross Profit	$1.6M	$3.4M-56.6%	$7.9M+27.6%	$6.2M+115.4%	$2.9M+159.0%	$1.1M-10.2%	$1.2M+34.1%	$916K+47.5%	$621K+221.8%	$193K+10.1%	$175K+167.5%	$66K+17.9%	$56K-59.8%	$138K+436.8%	$26K-76.9%	$111K
R&D Expenses	$3.3M	$2.6M-10.0%	$2.9M+26.3%	$2.3M+73.0%	$1.3M-3.5%	$1.4M+2.2%	$1.3M-9.1%	$1.5M-14.4%	$1.7M+5.5%	$1.6M+17.9%	$1.4M+101.9%	$685K+6.5%	$643K-13.4%	$742K+93.5%	$384K+285.5%	$99K
SG&A Expenses	$12.6M	$11.8M+26.5%	$9.3M+15.4%	$8.1M+19.7%	$6.7M+9.1%	$6.2M-17.4%	$7.5M+21.7%	$6.1M+15.5%	$5.3M+20.0%	$4.4M+19.2%	$3.7M+4.6%	$3.6M	N/A	N/A	N/A	N/A
Operating Income	-$18.1M	-$14.9M-243.0%	-$4.3M+5.4%	-$4.6M+15.0%	-$5.4M+20.5%	-$6.8M+10.6%	-$7.6M-13.2%	-$6.7M-4.4%	-$6.4M-8.8%	-$5.9M-19.5%	-$4.9M-18.0%	-$4.2M	N/A	N/A	N/A	N/A
EBITDA	N/A	-$14.6M-249.5%	-$4.2M+6.7%	-$4.5M+16.2%	-$5.3M+20.9%	-$6.8M+10.2%	-$7.5M-13.5%	-$6.6M-4.2%	-$6.4M-8.5%	-$5.9M-19.2%	-$4.9M-18.0%	-$4.2M	N/A	N/A	N/A	N/A
Interest Expense	$805K	$540K+660.6%	$71K-22.0%	$91K+71.7%	$53K-77.4%	$234K-87.8%	$1.9M-51.9%	$4.0M+14.4%	$3.5M-9.5%	$3.9M+23.4%	$3.1M+214.6%	$995K+185.7%	$348K+23.6%	$282K-54.3%	$616K-22.3%	$793K
Income Tax	N/A	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$18.8M	-$15.2M-249.4%	-$4.3M+6.5%	-$4.6M+9.4%	-$5.1M+25.6%	-$6.9M+28.9%	-$9.7M+15.2%	-$11.4M-7.0%	-$10.7M	N/A	-$8.1M-59.0%	-$5.1M	N/A	N/A	N/A	N/A
EPS (Basic)	N/A	-$0.04-300.0%	-$0.010.0%	-$0.01+50.0%	-$0.02+33.3%	-$0.03	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24S-1	Q3'2410-Q
Revenue	$1.2M-55.1%	$1.1M-65.9%	$616K-83.1%	$1.1M-74.6%	$2.8M-44.6%	$3.3M-31.3%	$3.7M-16.4%	$4.4M+62.8%
Cost of Revenue	$573K-57.7%	$657K-63.1%	$491K-74.2%	$731K-72.2%	$1.4M-52.9%	$1.8M-29.2%	$1.9M-16.4%	$2.6M+112.5%
Gross Profit	$675K-52.5%	$458K-69.2%	$125K-92.8%	$372K-78.4%	$1.4M-33.5%	$1.5M-33.7%	$1.7M-16.4%	$1.7M+20.0%
R&D Expenses	$1.1M+103.4%	$907K+14.7%	$652K-16.9%	$615K-10.9%	$535K-14.1%	$791K+0.9%	$785K+80.0%	$690K-0.6%
SG&A Expenses	$3.3M+23.3%	$2.8M+9.2%	$3.5M+34.5%	$3.1M+47.5%	$2.7M+11.8%	$2.5M+13.3%	$2.6M+13.8%	$2.1M-8.1%
Operating Income	-$3.7M-106.9%	-$3.2M-72.1%	-$4.0M-148.1%	-$7.2M-576.7%	-$1.8M-102.5%	-$1.9M-144.0%	-$1.6M-60.6%	-$1.1M+31.0%
EBITDA	-$3.7M-109.3%	-$3.2M-74.2%	-$3.9M-145.4%	-$7.1M-599.2%	-$1.8M-107.3%	-$1.8M-150.3%	-$1.6M-57.8%	-$1.0M+31.5%
Interest Expense	$285K+147.8%	$188K+102.2%	$188K+327.3%	$144K+1007.7%	$115K+5650.0%	$93K+675.0%	$44K+131.6%	$13K+8.3%
Net Income	-$4.0M-112.5%	-$3.4M-77.3%	-$4.1M-139.1%	-$7.2M-583.4%	-$1.9M-141.3%	-$1.9M-147.9%	-$1.7M-69.8%	-$1.1M+29.7%
EPS (Basic)	-$0.01-150.0%	-$0.01	-$0.01-100.0%	-$0.02-900.0%	$0.00-300.0%	$0.00+100.0%	-$0.01	$0.00+50.0%

Not reported in any period shown, so not listed: Income Tax, EPS (Diluted), Diluted Shares (Avg).

BLGO Balance Sheet

BLGO quarterly balance sheet

Metric	FY25S-1	FY24S-1	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$8.3M-20.9%	$10.5M+28.1%	$8.2M+68.9%	$4.9M+60.7%	$3.0M-38.8%	$4.9M+36.5%	$3.6M+13.7%	$3.2M+112.9%	$1.5M-29.2%	$2.1M+10.6%	$1.9M+632.8%	$261K+55.9%	$167K-37.8%	$269K+9.1%	$246K
Current Assets	$5.1M-28.3%	$7.1M+12.2%	$6.4M+101.8%	$3.2M+75.1%	$1.8M+19.7%	$1.5M+41.3%	$1.1M+11.5%	$955K-17.5%	$1.2M-42.6%	$2.0M+6.6%	$1.9M+720.1%	$231K+82.7%	$126K-41.8%	$217K+7.2%	$202K
Cash & Equivalents	$3.9M+9.4%	$3.5M+0.3%	$3.5M+91.2%	$1.9M+92.4%	$962K+34.4%	$716K+9.3%	$655K0.0%	$655K-33.8%	$990K-48.2%	$1.9M+8.3%	$1.8M+1041.5%	$154K+67.1%	$92K-38.9%	$151K+17.7%	$128K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$310K-6.1%	$330K+115.7%	$153K+27.5%	$120K-50.2%	$241K-13.0%	$277K+1631.3%	$16K-38.5%	$26K-51.9%	$54K+56.8%	$34K-8.0%	$37K+46.7%	$26K-14.5%	$30K-44.7%	$54K-12.7%	$62K
Accounts Receivable	$615K-80.6%	$3.2M+21.3%	$2.6M+145.5%	$1.1M+107.4%	$513K+6.0%	$484K+36.3%	$355K+38.1%	$257K+173.4%	$94K+38.2%	$68K+64.1%	$41K+637.6%	$6K+43.0%	$4K-66.1%	$12K+10.8%	$10K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$4.3M+156.9%	$1.7M+22.1%	$1.4M+6905.0%	-$20K+98.8%	-$1.6M-250.4%	$1.1M-81.3%	$5.8M+34.7%	$4.3M-23.1%	$5.6M+62.9%	$3.4M+120.6%	$1.6M+138.7%	$653K-10.8%	$732K+31.1%	$558K-68.3%	$1.8M
Current Liabilities	N/A	N/A	N/A	$1.6M+14.7%	$1.4M	N/A	$4.4M+74.8%	$2.5M-40.9%	$4.2M+265.1%	$1.2M+151.0%	$460K-29.6%	$653K-10.8%	$732K+31.1%	$558K-59.4%	$1.4M
Non-Current Liabilities	$1.7M	N/A	$1.3M+1.7%	$1.3M+77.5%	$716K	N/A	$1.4M-20.4%	$1.8M+31.3%	$1.4M-39.4%	$2.3M+639.0%	$309K	$0	$0	$0-100.0%	$390K
Long-Term Debt	$2.1M+92.7%	$1.1M+273.4%	$289K+21.9%	$237K+31.7%	$180K-64.5%	$507K-27.6%	$700K-45.8%	$1.3M-16.0%	$1.5M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.0M-54.3%	$8.9M+29.3%	$6.8M+40.3%	$4.9M+4.8%	$4.7M+20.6%	$3.9M+279.2%	-$2.2M-43.9%	-$1.5M+63.5%	-$4.1M-209.7%	-$1.3M-476.7%	$352K+189.7%	-$392K+30.6%	-$565K-95.0%	-$290K+80.9%	-$1.5M
Retained Earnings	-$161.3M-7.9%	-$149.5M-1.6%	-$147.1M-2.4%	-$143.6M-3.2%	-$139.1M-5.4%	-$132.0M-6.9%	-$123.5M-10.5%	-$111.7M-10.4%	-$101.2M-10.1%	-$91.9M-9.3%	-$84.1M-6.4%	-$79.0M-4.9%	-$75.3M-3.5%	-$72.8M-7.9%	-$67.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24S-1	Q3'2410-Q
Total Assets	$6.7M-46.6%	$8.6M-18.5%	$8.3M-20.9%	$9.1M-11.4%	$12.5M+24.3%	$10.5M+7.0%	$10.5M+28.1%	$10.3M+57.4%
Current Assets	$3.5M-61.9%	$5.4M-24.6%	$5.1M-28.3%	$5.8M-21.9%	$9.2M+29.2%	$7.2M+0.6%	$7.1M+12.2%	$7.4M+57.6%
Cash & Equivalents	$2.2M-37.0%	$4.1M+60.8%	$3.9M+9.4%	$4.5M+17.1%	$3.5M-27.2%	$2.6M-40.9%	$3.5M+0.3%	$3.9M+27.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$303K-31.8%	$292K-20.9%	$310K-6.1%	$409K+71.8%	$444K+152.3%	$369K+47.0%	$330K+115.7%	$238K+95.1%
Accounts Receivable	$724K-58.3%	$730K-82.7%	$615K-80.6%	$761K-76.3%	$1.7M-17.5%	$4.2M+70.2%	$3.2M+21.3%	$3.2M+120.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$9.4M+46.0%	$8.8M+61.4%	$4.3M+156.9%	$2.5M+47.6%	$6.4M+54.7%	$5.4M+217.8%	$1.7M+22.1%	$1.7M+429.8%
Current Liabilities	$4.8M+16.8%	$4.9M+46.2%	N/A	N/A	$4.1M+35.5%	$3.4M	N/A	N/A
Non-Current Liabilities	$4.6M+96.4%	$3.8M+86.5%	$1.7M	$2.5M+119.2%	$2.4M+105.3%	$2.0M+61.4%	N/A	$1.1M+13.8%
Long-Term Debt	N/A	N/A	$2.1M+92.7%	N/A	N/A	N/A	$1.1M+273.4%	$180K-38.6%
Total Equity	-$1.9M-121.2%	$1.8M-76.5%	$4.0M-54.3%	$6.6M-23.3%	$8.8M+45.9%	$7.6M-6.2%	$8.9M+29.3%	$8.6M+21.3%
Retained Earnings	-$166.3M-9.5%	-$163.6M-8.6%	-$161.3M-7.9%	-$158.3M-6.6%	-$151.8M-2.6%	-$150.7M-2.1%	-$149.5M-1.6%	-$148.5M-1.4%

Not reported in any period shown, so not listed: Goodwill.

BLGO Cash Flow Statement

BLGO quarterly cash flow statement

Metric	TTM	FY25S-1	FY24S-1	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$10.3M	-$8.3M-158.8%	-$3.2M-35.6%	-$2.4M+14.4%	-$2.8M+29.8%	-$3.9M+5.2%	-$4.2M+6.1%	-$4.4M-13.6%	-$3.9M+9.2%	-$4.3M-15.1%	-$3.7M-97.6%	-$1.9M	N/A	N/A	N/A	N/A
Depreciation & Amortization	N/A	$258K+66.5%	$155K+50.5%	$103K+128.9%	$45K+125.0%	$20K-65.5%	$58K-10.8%	$65K+30.0%	$50K+66.7%	$30K+118.4%	$14K+25.8%	$11K0.0%	$11K0.0%	$11K+101.1%	$5K-31.0%	$8K
Stock-Based Compensation	N/A	$3.0M+43.7%	$2.1M-2.9%	$2.1M+2.6%	$2.1M+10.6%	$1.9M-23.9%	$2.5M+61.6%	$1.5M+14.0%	$1.3M+21.0%	$1.1M+46.8%	$751K-59.0%	$1.8M	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$29K	N/A	N/A	N/A	N/A	N/A	$4K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$4.3M	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$51K	$435K+133.0%	-$1.3M-175.5%	-$478K-76.4%	-$271K-697.1%	-$34K+72.4%	-$123K-251.4%	-$35K+39.7%	-$58K-100.0%	-$29K+53.2%	-$62K	N/A	N/A	N/A	N/A	-$4K
Financing Cash Flow	$9.0M	$8.2M+85.2%	$4.4M-4.7%	$4.7M+17.8%	$4.0M-6.5%	$4.2M-2.5%	$4.3M-2.8%	$4.5M+22.6%	$3.6M+8.0%	$3.4M-15.1%	$4.0M+12.4%	$3.5M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24S-1	Q3'2410-Q
Operating Cash Flow	-$3.1M-44.3%	-$2.9M-59.4%	-$1.6M+17.0%	-$2.8M-70.3%	-$2.1M-1302.6%	-$1.8M-480.5%	-$1.9M-95700.0%	-$1.6M-93.8%
Depreciation & Amortization	$31K-13.9%	$34K-19.0%	$33K-17.5%	$34K-12.8%	$36K-5.3%	$42K+16.7%	$40K+344.4%	$39K-15.2%
Stock-Based Compensation	N/A	$699K+13.7%	N/A	N/A	N/A	$615K+26.0%	N/A	N/A
Investing Cash Flow	-$160K-183.3%	-$32K	-$13K+77.2%	$256K+756.4%	$192K+153.6%	$0+100.0%	-$57K+61.0%	-$39K+81.0%
Financing Cash Flow	$1.3M-54.9%	$3.2M+268.4%	$952K-40.2%	$3.6M+367.3%	$2.8M+183.6%	$866K-20.0%	$1.6M+109.2%	$764K+50.7%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

BLGO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BLGO quarterly financial ratios

Metric	FY25S-1	FY24S-1	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	43.9%-0.3pp	44.2%-6.2pp	50.3%+1.8pp	48.6%+5.0pp	43.6%-6.9pp	50.5%+1.3pp	49.2%+3.7pp	45.5%+8.1pp	37.4%-24.9pp	62.3%+11.0pp	51.3%+1.5pp	49.8%-32.5pp	82.3%+43.0pp	39.3%-32.0pp	71.3%
Operating Margin	-191.3%	-24.4%+13.1pp	-37.5%+54.2pp	-91.6%	-267.8%	-311.8%	-359.8%	-470.1%	-1142.6%	-1755.5%	-3277.5%	N/A	N/A	N/A	N/A
Net Margin	-195.6%	-24.4%+13.6pp	-38.0%+49.2pp	-87.2%	-272.4%	-398.9%	-614.7%	-784.2%	N/A	-2872.4%	-3979.4%	N/A	N/A	N/A	N/A
Return on Equity	-375.8%-326.7pp	-49.1%+18.8pp	-67.9%+37.3pp	-105.2%+43.0pp	-148.2%+103.3pp	-251.4%	N/A	N/A	N/A	N/A	-1443.2%	N/A	N/A	N/A	N/A
Return on Assets	-182.8%-141.4pp	-41.3%+15.3pp	-56.6%+49.0pp	-105.6%+122.4pp	-228.1%-31.8pp	-196.3%+119.6pp	-315.9%+19.9pp	-335.8%	N/A	-382.2%-116.4pp	-265.8%	N/A	N/A	N/A	N/A
Current Ratio	N/A	N/A	N/A	2.00+0.7x	1.31	N/A	0.24-0.1x	0.38+0.1x	0.27-1.5x	1.75-2.4x	4.11+3.8x	0.35+0.2x	0.17-0.2x	0.39+0.2x	0.15
Debt-to-Equity	0.51+0.4x	0.12+0.1x	0.040.0x	0.050.0x	0.04-0.1x	0.13	N/A	N/A	N/A	N/A	4.43	N/A	N/A	N/A	N/A
Asset Turnover	0.93-0.8x	1.69+0.2x	1.49+0.3x	1.21+0.4x	0.84+0.3x	0.490.0x	0.51+0.1x	0.43+0.1x	0.34+0.2x	0.13+0.1x	0.07-0.4x	0.43-0.6x	1.00+0.8x	0.24-0.4x	0.63
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-835.8%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24S-1	Q3'2410-Q
Gross Margin	54.1%+2.9pp	41.1%-4.4pp	20.3%-27.5pp	33.7%-5.8pp	51.2%+8.6pp	45.5%-1.7pp	47.8%0.0pp	39.6%-14.1pp
Operating Margin	-298.7%	-287.4%	-651.1%	-651.0%	-64.9%-47.1pp	-57.0%-40.9pp	-44.3%-21.2pp	-24.4%+33.1pp
Net Margin	-320.5%	-305.4%	-672.4%	-656.8%	-67.8%-52.2pp	-58.8%-42.5pp	-47.4%-24.1pp	-24.4%+32.1pp
Return on Equity	N/A	-190.7%-165.4pp	-102.5%-82.9pp	-110.1%-97.7pp	-21.5%-8.5pp	-25.3%-15.7pp	-19.6%-4.7pp	-12.4%+9.0pp
Return on Assets	-60.0%-44.9pp	-39.8%-21.5pp	-49.8%-33.4pp	-79.3%-69.0pp	-15.1%-7.3pp	-18.3%-10.4pp	-16.5%-4.0pp	-10.3%+12.8pp
Current Ratio	0.73-1.5x	1.10-1.0x	N/A	N/A	2.25-0.1x	2.14	N/A	N/A
Debt-to-Equity	N/A	4.90+4.2x	0.51+0.4x	0.39+0.4x	0.74+0.7x	0.71+0.7x	0.12+0.1x	0.020.0x
Asset Turnover	0.190.0x	0.13-0.2x	0.07-0.3x	0.12-0.3x	0.22-0.3x	0.31-0.2x	0.35-0.2x	0.420.0x

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BIOLARGO INC BLGO	FY2025	$7.8M	-$15.2M	N/A	$27.8M	—
KRAIG BIOCRAFT LABS INC KBLB	FY2025	N/A	-$3.6M	N/A	$100.4M	—
BLUE BIOFUELS INC BIOF	FY2025	N/A	-$2.9M	N/A	$35.3M	—

Where BIOLARGO INC Ranks

Frequently Asked Questions

What is BIOLARGO INC's annual revenue?

BIOLARGO INC (BLGO) reported $7.8M in total revenue for fiscal year 2025. This represents a -56.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BIOLARGO INC's revenue growing?

BIOLARGO INC (BLGO) revenue declined by 56.3% year-over-year, from $17.8M to $7.8M in fiscal year 2025.

Is BIOLARGO INC profitable?

No, BIOLARGO INC (BLGO) reported a net income of -$15.2M in fiscal year 2025.

What is BIOLARGO INC's EBITDA?

BIOLARGO INC (BLGO) had EBITDA of -$14.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does BIOLARGO INC have?

As of fiscal year 2025, BIOLARGO INC (BLGO) had $3.9M in cash and equivalents against $2.1M in long-term debt.

What is BIOLARGO INC's gross margin?

BIOLARGO INC (BLGO) had a gross margin of 43.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BIOLARGO INC's return on equity (ROE)?

BIOLARGO INC (BLGO) has a return on equity of -375.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BIOLARGO INC's operating cash flow?

BIOLARGO INC (BLGO) recorded an outflow of $8.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are BIOLARGO INC's total assets?

BIOLARGO INC (BLGO) had $8.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does BIOLARGO INC spend on research and development?

BIOLARGO INC (BLGO) invested $2.6M in research and development during fiscal year 2025.

How many shares does BIOLARGO INC have outstanding?

BIOLARGO INC (BLGO) had 320M shares outstanding as of fiscal year 2025.

What is BIOLARGO INC's debt-to-equity ratio?

BIOLARGO INC (BLGO) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BIOLARGO INC's return on assets (ROA)?

BIOLARGO INC (BLGO) had a return on assets of -182.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BIOLARGO INC's P/E ratio?

BIOLARGO INC (BLGO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $27.8M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is BIOLARGO INC's price-to-sales ratio?

BIOLARGO INC (BLGO) trades at 6.8x sales, its market capitalization divided by revenue of $4.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $27.8M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does BIOLARGO INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, BIOLARGO INC (BLGO) held $3.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.3M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is BIOLARGO INC's Piotroski F-Score?

BIOLARGO INC (BLGO) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BIOLARGO INC's earnings high quality?

BIOLARGO INC (BLGO) reported a net loss of $15.2M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BIOLARGO INC cover its interest payments?

BIOLARGO INC (BLGO) reported an operating loss of $14.9M against $540K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.